| 23824570-0#49#73#diseaseC2239176 |
527-1140 |
diseaseC2239176 |
denotes |
he pooled odds ratio (OR) with the corresponding 95 % confidence interval (95 % CI) to estimate the effect. Based on the inclusion criteria, six individual studies with 2,288 cases and 3,170 controls were included into our study. Overall, significant association between the XRCC3 Thr241Met variant and HCC risk was observed under the following contrast models (OR Met vs. Thr = 1.68, 95 %CI 1.08-2.62; OR MetMet vs. ThrThr = 5.54, 95 %CI 3.09-9.94; OR MetMet vs. ThrThr + ThrMet = 5.70, 95 % CI 4.24-7.64). Besides, the pooled ORs indicated that the XRCC3 Thr241Met polymorphism exerted risk effect on the HCC pa |
| 16#21#gene751749#73#diseaseC2239176 |
23824570-0#16#21#gene7517 |
23824570-0#49#73#diseaseC2239176 |
associated_with |
XRCC3,"he pooled odds ratio (OR) with the corresponding 95 % confidence interval (95 % CI) to estimate the effect. Based on the inclusion criteria, six individual studies with 2,288 cases and 3,170 controls were included into our study. Overall, significant association between the XRCC3 Thr241Met variant and HCC risk was observed under the following contrast models (OR Met vs. Thr = 1.68, 95 %CI 1.08-2.62; OR MetMet vs. ThrThr = 5.54, 95 %CI 3.09-9.94; OR MetMet vs. ThrThr + ThrMet = 5.70, 95 % CI 4.24-7.64). Besides, the pooled ORs indicated that the XRCC3 Thr241Met polymorphism exerted risk effect on the HCC pa" |
